Tamera M. Weisser Ph.D.

Dr. Tamera (Tammy) Weisser is co-leader of the global patent prosecution group at Jones Day, comprising more than 100 professionals worldwide. She has over 15 years of experience in global patent portfolio development, management, and enforcement in biotechnology, particularly in the areas of biologics and diagnostics. For example, on behalf of MedImmune (AstraZeneca), she managed the patent portfolio and strategy concerning the infant RSV antibody therapy, SYNAGIS®, a $500 million+/year drug. In addition, she developed a human antibody patent portfolio on behalf of Kyowa Hakko Kirin, subsequently licensed to Sanofi in a deal valued at $300+ million. On behalf of Isis Pharmaceuticals and Genzyme (Sanofi), she developed and managed the patent portfolio surrounding KYNAMRO®, the first systemic antisense drug to reach the market. Other representative clients include BioMarin, Celgene, Genomatica, and NGM Biopharmaceuticals.

Her practice also includes performing patent validity and freedom-to-operate analyses and conducting due diligence of patent portfolios for clients, including potential investors, acquirers, and licensees, such as venture capital firms and biotechnology companies. [1]